Immunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX - Free Report) from a sell rating to a hold rating in a report released on Tuesday.

Get Immunic alerts:

Separately, Piper Sandler reiterated an overweight rating and issued a $28.00 target price on shares of Immunic in a report on Tuesday, July 16th.

View Our Latest Stock Analysis on Immunic

Immunic Price Performance

Shares of IMUX remained flat at $1.33 during mid-day trading on Tuesday. The stock had a trading volume of 199,151 shares, compared to its average volume of 567,618. Immunic has a 52 week low of $0.95 and a 52 week high of $1.92. The company has a market capitalization of $119.81 million, a PE ratio of -0.73 and a beta of 1.76. The stock has a 50 day simple moving average of $1.26 and a 200 day simple moving average of $1.28.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. During the same period in the prior year, the company earned ($0.54) EPS. Equities research analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Ad StockEarnings

Forget polls, focus on these 5 tickers

With all the geopolitical tensions in the world… all the inflation… all the expectations of a new round of Fed interest rate cuts… It’s no wonder gold is on a tear. In fact, the yellow metal’s up about 23% for the year (and likely to march much higher). But did you know that gold miners are doing even better?

Click Here to Get Your Free Top 10 Gold Stocks Report

Institutional Investors Weigh In On Immunic

Hedge funds have recently added to or reduced their stakes in the company. Gratus Capital LLC boosted its position in shares of Immunic by 15.1% during the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company's stock valued at $2,912,000 after buying an additional 254,999 shares during the last quarter. Sierra Summit Advisors LLC bought a new stake in Immunic during the fourth quarter worth $487,000. Summit Trail Advisors LLC bought a new stake in Immunic during the first quarter worth $25,000. Vanguard Group Inc. lifted its holdings in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the period. Finally, BVF Inc. IL bought a new stake in shares of Immunic in the first quarter valued at $11,752,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

(Get Free Report)

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

→ Forget polls, focus on these 5 tickers (From StockEarnings) (Ad)

Should you invest $1,000 in Immunic right now?

Before you consider Immunic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.

While Immunic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here